← Back to Search

Strategy Training for Mild Cognitive Impairment (ForAging Trial)

N/A
Recruiting
Led By Juleen Rodakowski, OTD,MS,OTR/L
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of Mild Cognitive Impairment
Acknowledge difficulty with a daily activity
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to month 12
Awards & highlights

ForAging Trial Summary

This trial will test a new intervention, Strategy Training, to see if it can help prevent the progression of disability in 150 older adults with Mild Cognitive Impairment.

Who is the study for?
This trial is for older adults living in the community who have been diagnosed with Mild Cognitive Impairment (MCI) and are noticing difficulties with daily activities. It's not suitable for those with other central nervous system disorders, substance disorders within the last five years, severe psychiatric conditions like bipolar disorder or schizophrenia, untreated major depression, severe medical conditions limiting daily activity, or if pregnant.Check my eligibility
What is being tested?
The study is testing a non-drug intervention called Strategy Training against Enhanced Usual Care to see if it can slow down disability progression in people with MCI. Participants may also undergo PET Imaging using Pittsburgh Compound B to examine brain changes.See study design
What are the potential side effects?
Since this trial involves non-pharmacological interventions such as cognitive strategies rather than medications, side effects are minimal but could include potential discomfort from routine PET imaging procedures.

ForAging Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Mild Cognitive Impairment.
Select...
I struggle with a daily activity.
Select...
I have been diagnosed with Mild Cognitive Impairment.

ForAging Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to month 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to month 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in disability

ForAging Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Strategy TrainingExperimental Treatment1 Intervention
In addition to receiving everything in Enhanced Usual Care, participants will engage in 10 sessions over 5 weeks with a trained research interventionist. Participants will describe activities they do, no longer do, or have never done using the cards from the Activity Card Sort as a guide. The therapist will ask the participants to use this information to identify and prioritize activity-based goals to address in the remaining sessions. These sessions will take place in a location of the participant's choice and will last approximately 1 hour.
Group II: Enhanced Usual CareActive Control1 Intervention
Enhanced usual care will allow older adults to interact with services and support. All mental health treatment (e.g., medications that you may be taking) and psychotherapy (e.g. counseling or social services) will be documented and monitored. Furthermore, all participants assigned to Enhanced Usual Care will receive the same assessments as other participants. The close monitoring will track potential changes in symptoms (e.g., depressive symptoms), and participants will be referred to services as appropriate.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Strategy Training
2013
N/A
~180

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,716 Previous Clinical Trials
16,346,304 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,683 Previous Clinical Trials
6,930,708 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,658 Previous Clinical Trials
28,004,349 Total Patients Enrolled

Media Library

Strategy Training Clinical Trial Eligibility Overview. Trial Name: NCT03913637 — N/A
Mild Cognitive Impairment Research Study Groups: Enhanced Usual Care, Strategy Training
Mild Cognitive Impairment Clinical Trial 2023: Strategy Training Highlights & Side Effects. Trial Name: NCT03913637 — N/A
Strategy Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT03913637 — N/A
Mild Cognitive Impairment Patient Testimony for trial: Trial Name: NCT03913637 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are involved in this trial?

"Affirmative. Clinicaltrials.gov contains evidence that this medical trial, initially posted on July 31st 2019, is actively seeking participants. One hundred and fifty patients must be gathered from a single location for the study to continue."

Answered by AI

Is this medical experiment still recruiting participants?

"According to records from clinicaltrials.gov, this trial is actively scouting participants. The medical study was first announced on July 31st 2019 and the most recent amendment was made on July 14th 2022."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
What site did they apply to?
University of Pittsburgh
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I have not used any drugs for my MCI. MCI is very difficult and I would like relief.
PatientReceived 1 prior treatment
I haven't had anything that's helped with my mci.
PatientReceived 2+ prior treatments
~17 spots leftby Nov 2024